secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2022-02-18T23:59:59+00:00
Accession:  0001193125-22-046610
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places Homology's pheNIX gene therapy trial for PKU on clinical hold due to elevated liver tests
--------------------------------------------------------------------------------

- FDA notified Homology on Feb 16, 2022 that HMI-102 trial is on clinical hold to modify risk mitigation for elevated liver function tests.
- Company expects official clinical hold letter within 30 days and will provide update after FDA interactions.
- Clinical hold does not affect CMC/manufacturing or other programs (HMI-103 gene editing, HMI-203 for Hunter syndrome).
- Homology expects program updates for HMI-103 and HMI-203 by end of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522046610/0001193125-22-046610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000119312522046610/d286726d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-046610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer